11 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 11 of 11 clinical reviews.
Step-by-step caregiver guidance for administering Rezdiffra (resmetirom) to adolescents aged 12 to 17 with NASH/MAFLD, including dosing, storage, missed-dose rules, and monitoring benchmarks backed by FDA labeling and clinical trial data.
A clinical deep-dive into how resmetirom (Rezdiffra) may affect growth, puberty, bone, liver, and metabolic development in adolescents aged 12 to 17, including current evidence, FDA status, and what clinicians should monitor.
A clinical guide to transitioning adolescent patients (ages 12-17) on Rezdiffra (resmetirom) into adult hepatology and metabolic care, covering FDA approval status, trial data, monitoring protocols, and handoff logistics.
Complete caregiver guidance for administering Rezdiffra (resmetirom) to adults aged 65 and older with MASH: dosing, safety monitoring, drug interactions, and practical daily tips reviewed by the HealthRX medical team.
A clinician-reviewed guide covering how resmetirom (Rezdiffra) affects daily activities, exercise tolerance, and structured programs in adults aged 65 and older with metabolic dysfunction-associated steatohepatitis (MASH).
Resmetirom (Rezdiffra) is FDA-approved only for adults with MASH. This evidence-based guide covers the off-label status, pediatric MASH epidemiology, available trial data, dosing considerations, and clinical decision-making for adolescents ages 12 to 17.
A clinical review of resmetirom (Rezdiffra) use in patients aged 65 and older, covering MAESTRO-NASH trial subgroup data, pharmacokinetic considerations, dosing, drug interactions, and what off-label geriatric use means in practice.
A comprehensive clinical guide covering resmetirom's current regulatory status in pediatric patients under 12, liver disease progression in children, and the structured transition to adult hepatology care for MASLD/MASH.
Complete caregiver guidance for Rezdiffra (resmetirom) in children under 12, including dosing, administration steps, storage, missed-dose protocols, and safety monitoring, reviewed by the HealthRX medical team.
A clinical deep-dive into resmetirom (Rezdiffra) use in children under 12, covering thyroid hormone receptor biology, developmental risks, current FDA status, and what pediatric MASLD data actually show.
A clinician-reviewed guide covering school accommodations, physical activity guidelines, fatigue management, and daily-life considerations for children under 12 taking Rezdiffra (resmetirom) for MASLD/NASH.